Managed Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Florida Gynecology Oncology, Ft. Myers
Flavopiridol used as second-line chemotherapy of endometrial carcinoma
October 9th, 2005
Flavopiridol was evaluated as second-line chemotherapy of endometrial carcinoma. "A phase II study was conducted to determine the efficacy of single agent flavopiridol therapy in patients with recurrent or persistent endometrial adenocarcinoma refractory to established treatments. Eligible patients with measurable disease who failed primary therapy including one cytotoxic regimen were eligible for the trial," scientists in the United States reported. "They were treated with single agent flavopiridol (50 mg/m2/day, IV bolus days 1, 2, 3). Treatment was repeated every 21 days with dose adjustments made for toxicity. Patients were treated...
Source: Managed Care Law Weekly (2005-10-09)
|
